Personalis Collaborates with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics

 Personalis Collaborates with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics

Personalis Collaborates with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics

Shots:

  • The two companies collaborated to characterize the immune response to precision genetic therapeutics, utilizing Personalis’ advanced analytics
  • The collaboration will combine Sarepta’s expertise in precision genetic medicine and Personalis’ advanced neoepitope prediction to characterize certain types of the immune response, benefitting patients with the rare disease
  • The Personalis ImmunoID NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its customers with information on all the ~20,000 human genes, together with the immune system, from a single tissue sample

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post